Dr. Matthew Galsky, Director of GU Medical Oncology, The Tisch Cancer Institute, Mount Sinai, New York discusses clinical trial data and RWE in assessing treatment options for patients with high-risk urothelial carcinoma.

Click here to listen to the podcast.